The US biotech is aghast that the cost-effectiveness committee for England, Wales and Northern Ireland is minded to reject its effective but pricey SMA therapy which has gained blockbuster status already on strong sales elsewhere in Europe and the US.
The spinal muscular atrophy (SMA) drug Spinraza (nusinersen) continues to drive revenue growth at Biogen Inc., but a likely rejection from NICE means that any contributions to sales from the countries covered by the cost effectiveness watchdog will be a long time coming.
The company and patients who suffer from the rare neurodegenerative disease have expressed disappointment over NICE's draft guidance which does...
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
